Asset Details
Do you wish to reserve the book?
Pathological Complete Response in Locally Advanced ALK Fusion Gene–Positive Lung Adenocarcinoma following Salvage Surgery: A Case Report and Literature Review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pathological Complete Response in Locally Advanced ALK Fusion Gene–Positive Lung Adenocarcinoma following Salvage Surgery: A Case Report and Literature Review
Do you wish to request the book?
Pathological Complete Response in Locally Advanced ALK Fusion Gene–Positive Lung Adenocarcinoma following Salvage Surgery: A Case Report and Literature Review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pathological Complete Response in Locally Advanced ALK Fusion Gene–Positive Lung Adenocarcinoma following Salvage Surgery: A Case Report and Literature Review
2025
Overview
INTRODUCTION: Alectinib, a 2nd-generation anaplastic lymphoma kinase–tyrosine kinase inhibitor (ALK-TKI), is an established 1st-line therapy for advanced ALK fusion gene–positive non–small cell lung cancer (NSCLC). However, the role of salvage surgery following alectinib for locally advanced disease remains uncertain.CASE PRESENTATION: A 41-year-old woman was diagnosed in the postpartum period with Stage IIIA (cT1cN2M0) ALK fusion gene–positive lung adenocarcinoma. She received 1st-line alectinib, achieving a 55.3% reduction in tumor size over 11 months. Subsequent salvage surgery revealed a pathological complete response with no residual tumor cells. During postoperative follow-up off alectinib, recurrence was observed 20 months after surgery, with new brain and pulmonary metastases. Reintroduction of alectinib achieved renewed disease control, and the patient has remained progression-free for 23 months since restarting therapy.CONCLUSIONS: This case highlights the potential role of salvage surgery following alectinib in locally advanced ALK fusion gene–positive NSCLC. Furthermore, it suggests that maintenance ALK-TKI therapy after salvage surgery might be associated with a reduced risk of recurrence. Further studies are warranted to optimize perioperative ALK-targeted strategies.
Publisher
Japan Surgical Society,International Academic Publishing Co Ltd
